Innovative Medicine Backed by the Power of Artificial Intelligence

BioXcel Therapeutics, Inc., a clinical-stage biopharmaceutical company utilizing artificial intelligence, or AI, approaches to develop transformative medicines in neuroscience and immuno-oncology.

About Us

Company’s Approach to Drug Development

Company’s Approach to Drug Development

AI-based Drug Development

Our neuroscience and immuno-oncology programs utilize our AI approach to drug development.

BXCL501

BXCL501 is an investigational, proprietary, orally dissolving, thin film formulation of dexmedetomidine designed for the treatment of agitation and opioid withdrawal symptoms.

BXCL701

BXCL701 is an investigational, orally-administered, systemic innate immunity activator in development for the treatment of aggressive forms of prostate cancer and advanced solid tumors that are refractory or treatment naïve to checkpoint inhibitors.

Latest News

BioXcel Therapeutics to Highlight Novel Approaches in AI-Based Drug Candidate Discovery and Development and Advances in Neuroscience Portfolio at Virtual R&D Day

View Release

BioXcel Therapeutics Presents Results from Ongoing Phase 2 Trial of BXCL701 in Combination with KEYTRUDA® in Aggressive Forms of Prostate Cancer at ESMO

View Release

BioXcel Therapeutics to Present Updates from Ongoing Trial of BXCL701 in Aggressive Forms of Prostate Cancer at 2021 ESMO Congress

View Release
View all news

Sign up for Email Alerts

Email Sign Up

Stock Information

BioXcel Therapeutics, Inc.

View Investor Relations View Investor Presentation